Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that the first patient has been dosed in a Phase 1/2 clinical trial to assess the efficacy of its lead investigational drug, AEVI-001 (NFC-1), in children with 22q11.2 Deletion Syndrome (22q DS), a rare disorder caused by an abnormality found on the 22nd chromosome. The trial will evaluate the changes in symptoms associated with three neuropsychiatric disorders — including anxiety, attention deficit hyperactivity disorder (ADHD) and autism spectrum disorders (ASD) — that are often found in patients affected by 22q DS.

This entry was posted in Recent Development News: Q1 - 2017, Recent Developments. Bookmark the permalink.
Read Full Article »